JP2012516349A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516349A5
JP2012516349A5 JP2011548297A JP2011548297A JP2012516349A5 JP 2012516349 A5 JP2012516349 A5 JP 2012516349A5 JP 2011548297 A JP2011548297 A JP 2011548297A JP 2011548297 A JP2011548297 A JP 2011548297A JP 2012516349 A5 JP2012516349 A5 JP 2012516349A5
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
halogen
het
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011548297A
Other languages
English (en)
Japanese (ja)
Other versions
JP5658688B2 (ja
JP2012516349A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/022411 external-priority patent/WO2010088392A1/en
Publication of JP2012516349A publication Critical patent/JP2012516349A/ja
Publication of JP2012516349A5 publication Critical patent/JP2012516349A5/ja
Application granted granted Critical
Publication of JP5658688B2 publication Critical patent/JP5658688B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011548297A 2009-01-28 2010-01-28 カルボキサミド化合物およびその使用方法 Expired - Fee Related JP5658688B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14798209P 2009-01-28 2009-01-28
US61/147,982 2009-01-28
PCT/US2010/022411 WO2010088392A1 (en) 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same

Publications (3)

Publication Number Publication Date
JP2012516349A JP2012516349A (ja) 2012-07-19
JP2012516349A5 true JP2012516349A5 (enExample) 2013-03-14
JP5658688B2 JP5658688B2 (ja) 2015-01-28

Family

ID=42061132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548297A Expired - Fee Related JP5658688B2 (ja) 2009-01-28 2010-01-28 カルボキサミド化合物およびその使用方法

Country Status (17)

Country Link
US (2) US8362235B2 (enExample)
EP (1) EP2391616B1 (enExample)
JP (1) JP5658688B2 (enExample)
KR (1) KR101693061B1 (enExample)
CN (1) CN102365275B (enExample)
AU (1) AU2010208247B2 (enExample)
BR (1) BRPI1007287B8 (enExample)
CA (1) CA2750835C (enExample)
EA (1) EA022083B1 (enExample)
ES (1) ES2581678T3 (enExample)
IL (1) IL214203A (enExample)
MX (1) MX2011007639A (enExample)
NZ (1) NZ594556A (enExample)
SG (1) SG172974A1 (enExample)
UA (1) UA106600C2 (enExample)
WO (1) WO2010088392A1 (enExample)
ZA (1) ZA201105215B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722139C (en) 2008-04-23 2017-04-11 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
CA2806341C (en) * 2010-07-29 2020-03-24 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
WO2015048547A2 (en) * 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
WO2015046595A1 (ja) 2013-09-30 2015-04-02 国立大学法人東京大学 アディポネクチン受容体活性化化合物
US11597715B2 (en) 2018-01-11 2023-03-07 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
EP1319001A1 (en) * 2000-09-22 2003-06-18 Smithkline Beecham Plc Pyrazolopyridines and pyrazolopyridazines as antidiabetics
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
EP1932834B1 (en) 2006-12-11 2011-04-27 The Genetics Company, Inc. Aromatic 1,4-DI-Carboxylamides and their use
EP2079694B1 (en) * 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
KR101573091B1 (ko) 2007-11-16 2015-11-30 리겔 파마슈티칼스, 인크. 대사성 장애를 위한 카르복스아미드, 술폰아미드 및 아민 화합물
CA2707047C (en) * 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2722139C (en) * 2008-04-23 2017-04-11 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds

Similar Documents

Publication Publication Date Title
JP2012516349A5 (enExample)
JP2011503210A5 (enExample)
JP2011506480A5 (enExample)
TWI843712B (zh) K他命的前藥及其組成物及用途
ES2552733T3 (es) Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
JP6388991B2 (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
ES2942319T3 (es) Inhibidores de oxacina monoacilglicerol lipasa (MAGL)
JP2013532692A5 (enExample)
EP3101015B1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
JP2011527665A5 (enExample)
NO20091681L (no) Modulatorer av glukortikoidreseptoren, AP-1, og/eller NF-kappaB aktivitet og anvendelse derav
JP2010514788A5 (enExample)
ES2652664T3 (es) Anilinas sustituidas como antagonistas de CCR(4)
TW201024313A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2006513268A (ja) mGluR1−およびmGluR5−アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体
JP2013533229A5 (enExample)
JP2022510691A (ja) 線維症及び炎症の処置のための組成物
CN106714793B (zh) 琥珀酸脱氢酶抑制剂(SDHi’s)
RU2010108943A (ru) Новые пиперазинамидные производные
MX2010012067A (es) Derivados de 3,4-piperidina sustituida como inhibidores de la renina.
KR102766396B1 (ko) 복소환 술폰아미드 유도체 및 그것을 함유하는 의약
JP7600134B2 (ja) 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤
CN103649075B (zh) 1,4-二氢吡啶-3,5-二羧酸酯衍生物及其制备与应用